A US study said that a policy of regularly washing every patient in the intensive care unit with antimicrobial cloths helped cut down on dangerous blood infections by 44 percent.

The randomized study compared methods at 43 hospitals, including 74 ICUs and 74,256 patients.
The winning practice, known as "universal decolonization," involves giving patients a nasal dose of the antibiotic mupirocin twice daily for five days, and bathing patients daily with cloths covered in antimicrobial chlorhexidine for the entire ICU stay.
"Universal decolonization of patients in the ICU was the most effective strategy, significantly reducing MRSA-positive clinical cultures by 37 percent and bloodstream infections from any pathogen by 44 percent," said the study.
The method works by reducing the number of pathogens on the skin, "thus protecting patients in the ICU from their own microbiota during a period of heightened vulnerability to infection," said the study.
Also, by cutting back on the number of microbes, there were fewer opportunities for patient-to-patient spread of harmful pathogens.
Advertisement
The findings indicate that legislative mandates -- currently on the books in nine US states -- that require MRSA screening in the ICU may be misguided.
Advertisement
"The universal decolonization strategy was the most effective and the easiest to implement. It eliminates the need for screening ICU patients for MRSA," said Huang, medical director of epidemiology and infection prevention at University of California Irvine Health.
Washing all ICU patients this way could also cut down on unnecessary surveillance tests and do away with precautions over contacting patients who test positive, which can interfere with care, the researchers said.
However, some prior research has pointed to the possibility that widespread use of chlorhexidine and mupirocin could lead to MRSA resistance, so such efforts would need to be monitored carefully.
MRSA is priority target among health care associated infections because of its prevalence, virulence and multidrug resistant profile, said the study.
The study, known as the REDUCE MRSA trial, was carried out by the University of California, Irvine, Harvard Pilgrim Health Care Institute, Hospital Corporation of America (HCA) and the Centers for Disease Control and Prevention.
Source-AFP